Condition: Immune Thrombocytopenia · Treatment · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.
This description comes directly from the study's public registry record.
Lei Zhang, MD · +86 13502118379 · zhanglei1@ihcams.ac.cn
Ting Sun, MD · +8615822339131 · sunting@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06281327